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Abstract
Objectives—To compare the Vasculitis Damage Index (VDI) with the Combined Damage 
Assessment Index (CDA) as measures of damage from vasculitis.
Methods—A total of 283 patients with vasculitis from 11 European centres were evaluated in a 
cross-sectional study using the VDI and CDA.
Results—Wegener’s granulomatosis (58.4%) and microscopic polyangiitis (11.0%) were the 
most common diagnoses. Agreement between VDI and CDA scores (Spearman’s correlation) was 
0.90 (95% CI 0.87 to 0.92). There was good correlation between individual comparably evaluated 
organ systems (Spearman’s correlation 0.70–0.94). Interobserver reliability (assessed by intraclass 
correlation coefficient (ICC)) was 0.94 (95% CI 0.89 to 0.98) for VDI and 0.78 (95% CI 0.63 to 
0.93) for CDA. Intraobserver reliability was 0.92 (95% CI 0.83 to 1.00) for VDI and 0.87 (95% CI 
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0.75 to 1.00) for CDA. A total of 13 items were not used in the VDI compared to 23 in the CDA. 
Observers agreed that the CDA covered the full spectrum of damage attributable to vasculitis but 
was more time consuming and thus possibly less feasible for clinical and research purposes.
Conclusions—The VDI and CDA capture reliable data on damage among patients with 
vasculitis. The CDA captures more detail but is more complex and less practical than the VDI. 
Further evolution of damage assessment in vasculitis is likely to include key elements from both 
instruments.
INTRODUCTION
The prognosis for a patient with systemic vasculitis has improved with treatment.1–6 
However, the long-term outlook is characterised by morbidity from recurrent flares, low-
grade grumbling disease and/or accumulation of damage from previous disease activity or 
treatment.6–9 Systematic recording and quantification of damage allows recording of the 
natural history of the disease, provides distinction from disease activity and can be used as 
an outcome measure for clinical trials.10
The Vasculitis Damage Index (VDI) is a validated11 method for measuring damage sustained 
from vasculitis or its treatment. It was developed by consensus by a group of vasculitis 
experts and is widely used in clinical trials.412–14 However, the VDI may not adequately 
capture all damage caused by small and medium vessel vasculitis or treatment.10 A group of 
international experts in vasculitis from Europe and the USA constructed a new tool to 
measure damage called the Combined Damage Assessment Index (CDA). It is based on the 
VDI,10 and includes additional items of damage that were recorded in the Wegener’s 
Granulomatosis Etanercept Trial (WGET) but not captured by individual items on the 
VDI.910
The VDI comprises 64 items grouped into 11 categories. The CDA has 135 individual items 
in 17 categories, and includes some bilaterality for items involving the eyes and ears; 8 items 
assign gradation. The VDI and the CDA measure damage that has occurred since the onset 
of vasculitis; pre existing comorbidity is not counted.
The Outcome Measures in Rheumatology (OMERACT) filter consists of the following 
criteria. (1) Truth: does it measure what it intends to measure? (2) Discrimination: does it 
discriminate from situations of interest? (3) Feasibility: can the measure be easily applied 
given the constraints of time, money and interpretability?15
The objective of this study was to: (1) compare the performance of the CDA to the VDI in a 
cross-sectional study of patients with vasculitis, (2) begin to evaluate the CDA with respect 
to the OMERACT filter and (3) review the use of individual items in VDI and CDA.
METHODS
Consecutive patients (inpatient and outpatients) with new or existing diagnoses of vasculitis 
were recruited from 11 European centres. Local medical ethics requirements were met by 
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each participating site. Participants gave their written informed consent before participating 
in the study.
Basic demographics, type of vasculitis, duration of disease, C reactive protein (CRP) and 
anti-neutrophil cytoplasmic antibody (ANCA) results were obtained on each patient. 
Patients were assessed for disease activity using the Birmingham Vasculitis Activity Score 
version 3 (BVAS v3)16 and disease damage using the VDI and CDA by an observer at each 
site (total of 11 observers). All forms were completed in English. For the purpose of this 
study any damage scored had to be present following the onset of vasculitis and be present 
for at least 3 months. The total VDI score and the total CDA score are each represented by 
the cumulative number of items that are recorded, respectively. The VDI and CDA scores 
can stay the same or worsen over time, but cannot improve. Each item in CDA or VDI 
contributes 1 point to the total score.17
Convergent validity measures the extent to which assessments that are theoretically related 
to each other are actually related. In this case VDI and CDA should be closely correlated. 
Convergent validity was assessed by comparing overall VDI and CDA scores as well as 
individual organ scores. To evaluate discrimination we assessed the relationship between the 
damage assessment tools with the BVAS v3, CRP and ANCA result. In addition, 
interobserver and intraobserver reliability was investigated. A total of 28 (9.9%) patients 
were scored by 2 different observers at the same time point and 14 (4.9%) by the same 
observer at 2 different time points within 3 months of each other. This was the total number 
achieved during the study and not specifically chosen, but our expectation was that using 
trained observers would demonstrate good agreement based on previous experience with the 
VDI.11
In addition to real patients, a VDI and CDA were completed on up to 20 different paper 
cases by an independent group of specialist doctors, fellows and research nurses with an 
interest in vasculitis. The paper cases were used to assess feasibility only. The paper cases 
were designed on real cases seen by RL and CM but modified in order to encompass the 
range of items recorded in the VDI and CDA. The observers were provided with written 
instructions on how to complete the assessment. All observers who completed a CDA and a 
VDI on patients or paper cases were invited to complete a feasibility questionnaire for each 
of the damage assessment tools. The feasibility questionnaire was a series of 10 statements 
or questions that the respondents had to rate or answer on a 4-point Likert scale.
We identified unused items in VDI from the current study and combined data published on 
damage assessment in the WGET trial9 and from unpublished 5-year follow-up results from 
the European Vasculitis Study Group (EUVAS) cohorts4131819 to provide a large sample of 
patients to determine the potential redundancy of VDI items.
Statistical analysis
Stata V.10, (StataCorp, College Station Texas, USA) was used for analysis. The distributions 
of the BVAS v3, VDI and CDA scores were not normally distributed so we used a 
nonparametric approach based on ranks to measure their correlation. Spearman’s rank 
correlation coefficient was calculated by independently ranking the VDI and CDA scores, 
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then calculating the Pearson correlation between the ranks rather than the original 
measurements. We used the intraclass correlation coefficient (ICC) to calculate interobserver 
and intraobserver reliability for overall VDI and CDA scores. This method estimates the 
average correlation between all possible orderings of pairs and was calculated using a one-
way analysis of variance. To assess interobserver reliability between observers for each of 
the categories in the VDA and CDA a linear-weighted κ statistic was calculated, in which 
observed and expected proportions of agreement are modified to include partial agreements 
by assigning a weight between 0 (complete disagreement) and 1 (complete agreement) to 
each category. The 17 subcategories of the CDA were collapsed into the same 11 categories 
of the VDI for this analysis.
RESULTS
A total of 283 patients (51% women, 49% men) with vasculitis were evaluated. Disease 
duration ranged from 0 to 480 months. A summary of the range of diagnosis, VDI and CDA 
scores and disease duration is shown in table 1. Wegener’s granulomatosis (58.4%) and 
microscopic polyangiitis (11.0%) were the most common diagnoses. The remaining patients 
were a mixture of other primary and secondary vasculitis. The scores ranged from 0 to 12 
for the VDI and 0 to 26 for the CDA, with the largest range seen in patients with Wegener’s 
granulomatosis with renal involvement. Table 2 shows organ system involvement as 
recorded by each of the damage tools. Of the 192 patients with a disease duration of at least 
12 months, 170 (89%) had some damage recorded on the VDI compared to 176 (92%) on 
the CDA (as determined by a score >0 on each tool, respectively).
Convergent validity
Measurements taken in an individual patient on the same date for VDI and CDA scores were 
paired together. In instances where more than one paired observation was available in a 
single patient (ie, patients assessed twice to calculate interobserver or intraobserver 
reliability), one of the paired observations was randomly chosen. For the total VDI and CDA 
scores there was a high positive correlation (ρ=0.90, p<0.001); a graphical representation of 
this is shown in figure 1. There was a high positive correlation between the organ system 
scores, except for ‘skin/mucous membrane’, where there was a moderate correlation 
(ρ=0.47, p<0.001). When the two skin-related items found in CDA but not VDI, ‘easy 
bruising’ (15.8% of patients) and ‘cutaneous scarring’ (9.0%) in the CDA, were removed 
from the analysis, the correlation was 0.70 (p<0.001). A complete list of the correlations 
between the organ systems between the VDI and CDA is provided in table 2.
Discrimination
The correlation (Spearman’s ρ) with BVAS 2003 was −0.17 (95% CI −0.28 to −0.05) and 
−0.19 (95% CI −0.30 to −0.07); CRP −0.09 (95% CI −0.21 to 0.04) and −0.12 (95% CI 
−0.24 to 0.01); ANCA −0.26 (95% CI −0.45 to −0.06) and −0.32 (95% CI −0.49 to −0.12), 
for VDI and CDA, respectively. This shows that there was no correlation between the two 
measures of disease damage with measures of disease activity or items considered unrelated 
to disease damage.
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Reliability
The interobserver reliability using the ICC was 0.94 (95% CI 0.89 to 0.98) for the VDI and 
0.78 (95% CI 0.63 to 0.93) for the CDA. The interobserver reliability was better for patients 
with short compared with long disease duration: ICC was 0.99 (95% CI 0.97 to 1.00) and 
0.87 (95% CI 0.74 to 0.99) for disease duration ≤3 years versus 0.90 (95% CI 0.79 to 1.0) 
and 0.67 (95% CI 0.33 to 1.0) for disease duration >3 years on the VDI and CDA, 
respectively. Observations for intraobserver reliability were restricted to patients who were 
reassessed by the same observer within 3 months (14 patients for the VDI, 15 patients the 
CDA). The intraobserver reliability was 0.92 (95% CI 0.83 to 1.00) for the VDI and 0.87 
(95% CI 0.75 to 1.00) for the CDA. There were not enough patients to determine 
intraobserver reliability stratified by disease duration. The κ statistics for the individual 
systems for interobserver and intraobserver reliability (table 3) demonstrated fair to good 
agreement, although CIs were wide due to small numbers (only 3/28 patients had any items 
recorded in the musculoskeletal system). No individual musculoskeletal item could account 
for the wide CIs.
The use of individual items
Table 4 shows the 10 most commonly used items for each of the damage assessment tools. 
The items mainly comprised upper respiratory tract, renal, auditory features and peripheral 
neuropathy (in keeping with Wegener’s granulomatosis being the most common diagnosis). 
Items frequently used in the CDA, but not captured by the VDI were easy skin bruising 
(15.8%), weight gain >10 lbs/4.4 kg (14.8%) and cutaneous scarring (9.0%). Due to the 
increase number of options for recording damage on the CDA this has resulted in 
discrepancy in scoring items on the CDA compared to the VDI. For example, the proportion 
of patients with glomerular filtration rate <50% is different between the two assessment 
tools, primarily because there are other options on the CDA for recording renal impairment.
A total of 13 items of damage were not used in the VDI; 11 additional items were used less 
than 1% of the time. In comparison, the CDA had 23 items of damage, 4 gradations of 
severity and 2 items attributing causality that were not used. There were an additional 45 
items that were used less than 1% of the time. Table 5 shows a list of the least used items in 
both damage tools.
Redundant items on the VDI
Combining our study population with the WGET trial and patients with 5 years of follow-up 
in the EUVAS cohorts represent a total of 804 patients. The following seven items of 
damage were not used in the VDI in this combined population: second episode of fresh loss 
of pulses in one limb, chronic peritonitis, major psychosis, oesophageal stricture/upper 
gastrointestinal surgery, pericarditis ≥3 months/pericardectomy, subsequent major tissue loss 
and subsequent myocardial infarction.
Feasibility
In all, 12 observers completed the feasibility questionnaire (including 7/11 observers who 
scored the VDI and CDA in real patients and 5 who completed paper cases only). The five 
observers who completed the paper cases only were new users to both tools. Completion 
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time was 5–10 min (range: <5–10 min) for VDI compared to 10–15 min (<5–20 min) for 
CDA. Experienced users completed both assessments in <5 min. In all, 10 observers (83%) 
reported that the VDI and CDA were useful to record the natural history of vasculitis. All 
observers stated that the CDA covered the full spectrum of damage attributable to vasculitis 
compared to 7/12 (58%) for the VDI. In all, 8 (67%) observers said that the VDI was a 
practical tool for clinical use compared to 5/12 (42%) for the CDA; however, only 7/12 
(58%) and 3/12 (25%), respectively, would use it in clinical practice. Nine (75%) observers 
found the VDI easy to complete compared to five (42%) for the CDA. All observers stated 
that the VDI was a useful tool to measure outcomes in clinical trials whereas two disagreed 
with this statement for the CDA. Overall preference for the tools was mixed; 8/12 (67%) 
favoured the VDI. The CDA was preferred by some experienced observers, especially by 
those individuals who could complete both tools in a similar timeframe.
DISCUSSION
Damage assessment represents the permanent cumulative burden of disease morbidity from 
vasculitis or its treatment. It records the disease course, identifies the manifestations that do 
not warrant further immunosuppressive treatment and serves as an outcome measure in 
clinical trials.17 Both tools evaluated in this study serve this function well but have 
contrasting benefits and drawbacks.
The level of damage detected is consistent with previous reports; 89% of patients with at 
least 12 months of disease duration had ≥1 item of damage captured by VDI and 92% by 
CDA. This compares to 89% in the WGET trial.9 A Norwegian study of Wegener’s 
granulomatosis showed 100% of patients having damage by the end of follow-up (mean 4.7 
years)20; and a UK series with systemic vasculitis demonstrated 96% with a VDI score of ≥1 
by the end of follow-up (mean 6.1 years).21 The median disease duration of 39 months in 
this study may have been too short to detect some items of damage such as malignancy 
which was recorded in only 1.4% of patients. However, the relationship between vasculitis 
and malignancy is complex.822–25
The advantages of the VDI are that it is simple to complete, has very good reliability and is a 
widely accepted outcome measure in clinical trials,4913 with proven prognostic value. A 
score ≥1 at diagnosis predicts increased mortality and future organ damage.20 The VDI was 
preferred by the majority of observers in this study, mainly due to its relative simplicity, 
especially by less experienced users, which is of key importance if it is to be used 
infrequently in clinical practice. However, the main application of the VDI is in clinical 
trials, where it functions as a generic damage assessment tool for all types of vasculitis, 
thereby enabling widespread use, which facilitates familiarity, accuracy and completion 
speed.
The CDA is intended for use in clinical trials of ANCA associated vasculitis. The CDA is 
more comprehensive than the VDI, and may be more sensitive in detecting damage. In 
addition, the ranges of scores are larger and may be better at detecting change, although this 
was not tested in the current study. The CDA takes longer to complete than the VDI in less 
experienced observers, but the difference was minimal among experienced investigators. In a 
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clinical trial setting where more investment in training is available and there is less time 
pressure, the increased level of data capture by the CDA may be more desirable. There is 
disagreement among experts as to whether or not we should move towards disease-specific 
assessment tools in vasculitis clinical trials (ie, whether specific forms should be used for 
specific types of vasculitis, or if VDI could apply to types of vasculitis).1026 The benefit of 
increased sensitivity of a disease-specific tool such as the CDA has to be balanced against 
more limited application (ie, confined to use only in ANCA vasculitis). In addition, if 
multiple tools are developed for different forms of vasculitis, it reduces the ability for 
comparison between broadly similar conditions. Ultimately it may be useful to discuss a 
damage form that has a generic component and a specific component.
Gradations of severity and weighting of items are not adequately captured by existing 
damage tools. Intuitively, some forms of damage or gradations of severity may have more 
impact on a patient’s quality of life or prognosis than others. The future weights applied to 
individual items on the CDA or VDI should improve the correlation between mortality and 
quality of life.17 Efforts are underway to address this.27 In addition, there are redundant 
items in both tools; the seven unused items on the VDI (from WGET and EUVAS studies) 
could be omitted from any future damage tools that are specific for ANCA associated 
vasculitis in order to simplify the forms. Even if these items are removed from the main 
form, they will be retained in the glossary under ‘other items’ so these less common items 
can be recorded and contribute to the index. However, unused items such as cardiomyopathy 
or loss of pulses may be important for some diseases (eg, Takayasu’s disease) therefore 
should be retained in generic damage assessment tools.
There are limitations in this study. Study observers were already familiar with the VDI from 
previous clinical or trial experience whereas for most investigators, this study was the first 
time they used the CDA. This may explain the lower interobserver and intraobserver 
reliability of the CDA. Further training and more experience with the CDA could improve its 
reliability and acceptability. The current study is cross-sectional, and therefore cannot 
demonstrate changes to the CDA over time. Grading severity of individual items and 
allowing resolution of items may influence its correlation with quality of life indices and 
mortality. The classification of patients with less well defined forms of disease is difficult 
and there may be overlap between the categories listed in table 1. This is the real-life setting 
and therefore inclusion of these heterogeneous patients allows for the generalisability of our 
results.
In summary, this is the first study to test the CDA as a measure of damage in vasculitis. We 
have started evaluating the CDA with respect to the OMERACT filter, but more experience, 
especially in a longitudinal setting is required. The VDI remains the standard for damage 
assessment in vasculitis, and this study further validates its use. If there is move toward 
disease-specific damage assessment, then future revisions including a weighting system are 
likely to serve as outcome measures for trials in ANCA associated vasculitis.
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Refer to Web version on PubMed Central for supplementary material.
Suppiah et al. Page 7
Ann Rheum Dis. Author manuscript; available in PMC 2016 August 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
We thank Drs M Chan, A Miller, J Robson, A Soni and R Waller, for completing paper cases and answering the 
feasibility questionnaire. RS was supported by the Rose Hellaby Medical Scholarship, New Zealand. CM received 
support from the European League Against Rheumatism via a project grant held by RL. AJ was supported by NIHR 
BRU Musculoskeletal Research Group, University of Oxford. DRWJ was supported by the Cambridge Biomedical 
Research Centre. MAL was supported by a HEFCE new blood Senior Lecturer grant.
Funding This study was substantially funded by a project grant from the European League Against Rheumatism 
(EULAR) with additional support from the US National Institutes of Health (grants U54 RR019497, 
U54AR057319 and U01 AR1874).
References
1. Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol. 1952; 22:777–90. [PubMed: 
14943695] 
2. Godman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. AMA 
Arch Pathol. 1954; 58:533–53. [PubMed: 13217569] 
3. Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma 
exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004; 51:482–7. 
[PubMed: 15188337] 
4. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage 
methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 
18:2180–8. [PubMed: 17582159] 
5. Jayne D. Challenges in the management of microscopic polyangiitis: past, present and future. Curr 
Opin Rheumatol. 2008; 20:3–9. [PubMed: 18281850] 
6. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of anti-neutrophil cytoplasm 
antibody associated vasculitis: a systematic review by the European League Against Rheumatism 
systemic vasculitis task force. Ann Rheum Dis. 2008; 67:1004–10. [PubMed: 17911225] 
7. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, 
microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 
278 patients. Arthritis Rheum. 2001; 44:666–75. [PubMed: 11263782] 
8. Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and 
Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to 
steroids and plasma exchange. A prospective randomized trial of 71 patients. The cooperative study 
group for polyarteritis nodosa. J Rheumatol. 1991; 18:567–74. [PubMed: 1676753] 
9. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener’s granulomatosis and its treatment: 
prospective data from the Wegener’s granulomatosis etanercept trial (WGET). Arthritis Rheum. 
2005; 52:2168–78. [PubMed: 15986348] 
10. Seo P, Luqmani RA, Flossmann O, et al. The future of damage assessment in vasculitis. J 
Rheumatol. 2007; 34:1357–71. [PubMed: 17552062] 
11. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis 
damage index for the standardized clinical assessment of damage in the systemic vasculitides. 
Arthritis Rheum. 1997; 40:371–80. [PubMed: 9041949] 
12. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005; 352:351–61. 
[PubMed: 15673801] 
13. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis 
associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349:36–44. 
[PubMed: 12840090] 
14. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction 
methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended 
follow-up and rate of relapse. Am J Med. 2003; 114:463–9. [PubMed: 12727579] 
15. Boers M, Brooks P, Strand CV, et al. The OMERACT filter for outcome measures in 
Rheumatology. J Rheumatol. 1998; 25:198–9. [PubMed: 9489805] 
Suppiah et al. Page 8
Ann Rheum Dis. Author manuscript; available in PMC 2016 August 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessment in 
systemic vasculitis. Ann Rheum Dis. 2007; 66:283–92. [PubMed: 16728460] 
17. Merkel PA, Herlyn K, Mahr AD, et al. Progress towards a core set of outcome measures in small-
vessel vasculitis. Report from OMERACT 9. J Rheumatol. 2009; 36:2362–8. [PubMed: 19820226] 
18. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of 
remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann 
Intern Med. 2009; 150:670–80. [PubMed: 19451574] 
19. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus 
methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-
associated vasculitis. Arthritis Rheum. 2005; 52:2461–9. [PubMed: 16052573] 
20. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. 
Rheumatology (Oxford). 2002; 41:572–81. [PubMed: 12011383] 
21. Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is 
an index of outcome. QJM. 1997; 90:391–9. [PubMed: 9205677] 
22. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: 
incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 
2008; 35:100–5. [PubMed: 17937462] 
23. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener’s granulomatosis: risks 
and relation to cyclophosphamide. Ann Rheum Dis. 2004; 63:1307–11. [PubMed: 15130900] 
24. Koldingsnes W, Gran JT, Omdal R, et al. Wegener’s granulomatosis: long-term follow-up of 
patients treated with pulse cyclophosphamide. Br J Rheumatol. 1998; 37:659–64. [PubMed: 
9667621] 
25. Wooten MD, Jasin HE. Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum. 1996; 
26:564–74. [PubMed: 8916300] 
26. Merkel PA, Seo P, Aries P, et al. Current status of outcome measures in vasculitis: focus on 
Wegener’s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol. 
2005; 32:2488–95. [PubMed: 16331794] 
27. Seo P, Jayne D, Luqmani R, et al. Assessment of damage in vasculitis: expert ratings of damage. 
Rheumatology (Oxford). 2009; 48:823–7. [PubMed: 19454608] 
Suppiah et al. Page 9
Ann Rheum Dis. Author manuscript; available in PMC 2016 August 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Scatterplot showing ranked Vasculitis Damage Index (VDI) versus Combined Damage 
Assessment Index (CDA) scores. Patients with the same score (ties) were assigned the 
average rank. For example, 66 patients had a CDA score of 0. Therefore, patients 1 to 66 
were assigned the rank of (1+66)/2=33.5. The next 23 patients had a CDA score of 1 (in 
order 67 to 89), so the rank was (67+89)/2=78, and so forth.
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Table 3
Interobserver and intraobserver reliability of measurement of damage in vasculitis for each organ system
Organ system
Interobserver reliability, κ (95% CI) Intraobserver reliability, κ (95% CI)
VDI (n=28 paired 
observations)
CDA (n=28 paired 
observations)
VDI (n=14 paired 
observations)
CDA (n=15 paired 
observations)
Musculoskeletal 0.65 (0.02 to 1.00) 0.65 (0.02 to 1.00) – –
Skin/mucous membrane 0.78 (0.59 to 1.00) 0.59 (0.32 to 0.83) 1.00 (1.00 to 1.00) 0.41 (0.00 to 0.65)
Ocular 1.00 1.00 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)
ENT 0.77 (0.46 to 1.00) 0.59 (0.23 to 0.84) 0.79 (0.46 to 1.00) 0.78 (0.50 to 0.96)
Pulmonary 1.00 0.78 (0.37 to 1.00) 1.00 (1.00 to 1.00) 0.76 (0.32 to 1.00)
Cardiovascular 0.83 (0.60 to 1.00) 0.63 (0.42 to 0.84) 1.00 (1.00 to 1.00) 0.77 (−0.07 to 1.00)
Peripheral vascular 1.00 0.31 (−0.82 to 1.00) – –
Gastrointestinal – – – –
Renal 0.80 (0.19 to 1.00) 0.70 (0.40 to 0.88) 0.82 (0.45 to 1.00) 0.45 (0.00 to 0.88)
Neuropsychiatric 0.52 (0.11 to 0.92) 0.46 (0.00 to 0.92) 0.76 (0.32 to 1.00) 0.58 (0.07 to 1.00)
1.00, complete agreement; –, No patients had damage in this organ system; CDA, Combined Damage Assessment Index; ENT, ear, nose and throat; 
VDI, Vasculitis Damage Index.
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Table 4
The 10 most commonly used individual items of damage in vasculitis
VDI % CDA %
Nasal blockage/crusting 22.3 Chronic rhinitis/crusting 26.6
Peripheral neuropathy 21.9 Hypertension* 21.6
Hearing loss 19.1 Sensory neuropathy† 21.6
Hypertension 16.6 Proteinuria <3 g/24 h 17.6
Proteinuria 16.6 Easy bruising 15.8
GFR<50% 15.1 Weight gain >10 lbs/4 kg 14.8
Osteoporosis 11.9 Conductive hearing loss 13.7
Chronic sinusitis 11.5 GFR<50% 13.3
Nasal bridge collapse   9.7 Chronic kidney disease 12.6
Cataract   9.0 Osteoporosis 12.6
*
This includes patients with prehypertension, or stage 1 or stage 2 hypertension.
†
Includes patients with mild, moderate or severe sensory neuropathy.
CDA, Combined Damage Assessment Index; GFR, glomerular filtration rate; VDI, Vasculitis Damage Index.
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Table 5
Least used items in the VDI and CDA in patients with vasculitis
Items not used Items used <1%
VDI:
Second episode fresh loss of pulses in one limb*† Deforming/erosive arthritis*
Second cerebrovascular accident* Cardiomyopathy
Blindness other eye Claudication
Chronic peritonitis*† Gut infarction/resection
Major psychosis*† Major tissue loss†
Mesenteric insufficiency/pancreatitis* Marrow failure
Minor tissue loss Myocardial infarction*
Oesophageal stricture/upper GI surgery*† Pleural fibrosis
Osteomyelitis† Pulmonary infarction
Pericarditis ≥3 months/pericardectomy*† Seizures*†
Pulmonary hypertension† Transverse myelitis*
Subsequent major tissue loss*†
Subsequent myocardial infarction*†
CDA:
Auricular cartilage deformity left Auricular cartilage deformity right
Cervical cancer Bladder cancer
Cholesteatoma left Continuous oxygen dependency
Cholesteatoma right Gangrene with permanent tissue loss
Chronic peritonitis Gut infarction/resection
Haematopoetic malignancy Hepatic fibrosis
Mesenteric insufficiency/pancreatitis Impaired fasting glucose
Myelodysplastic syndrome Optic nerve oedema left
Oesophageal stricture/surgery Pericarditis or pericardiectomy
Optic nerve oedema right Pleural fibrosis
Osteomyelitis Pseudotumour left eye
Percutaneous coronary intervention Pseudotumour right eye
Pulmonary hypertension Pulmonary infarction
Refractory cytopenia Retinal artery occlusion left
Retinal artery occlusion right Retinal changes left
Retinal vein occlusion right Retinal vein occlusion left
Scleral perforation left Scleral thinning left
Scleral perforation right Scleral thinning right
Second cerebrovascular accident Second episode of absent pulses in one limb
Subsequent major tissue loss Tissue loss (includes major and minor)
Third degree AV block
Transverse myelitis
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Items not used Items used <1%
Vena caval filter
For VDA, items used <1%. For CDA, items used <0.05%
*
Items not used in the WGET trial cohort, n=180 patients.9
†
Items not used in the long-term follow-up (5 year VDI) of the EUVAS cohorts, n=339 patients (EUVAS trial physicians, unpublished results).
AV, atrioventricular; CDA, Combined Damage Assessment Index; EUVAS, European Vasculitis Study Group; GI, gastrointestinal; VDI, Vasculitis 
Damage Index; WGET, Wegener’s Granulomatosis Etanercept Trial.
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